Alimera Sciences Appoints Jason Werner as Chief Operating Officer
03 10월 2023 - 9:00PM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global
pharmaceutical company whose mission is to be invaluable to
patients, physicians, and partners concerned with retinal health
and maintaining better vision longer, today announced the
appointment of Jason Werner, Chief Operating Officer (“COO”),
effective October 2, 2023. In conjunction with this
appointment, Dr. Philip Ashman, previously Alimera’s Chief
Operating Officer and Senior Vice President, Commercial Operations
Europe, was appointed President of International Operations.
“Jason has been a strong voice and insightful influence on our
board since joining earlier this year, and we are grateful to him
for transitioning to this extremely important operational role,”
said Rick Eiswirth, President and CEO of Alimera. “His extensive
background in ophthalmics, along with his experience in previous
roles in commercial development and corporate strategy, will be
ideal in overseeing our manufacturing and regulatory efforts
globally as we accelerate our growth trajectory.”
Mr. Werner has served as a director of Alimera since Q2
2023. Prior to joining Alimera’s management team he has served
as the Chief Executive Officer and Board Member of SightStream
Biotherapeutics Inc, a biotechnology company focused on developing
regenerative medicines in ophthalmics. Mr. Werner also currently
serves on the board of directors of InflammX Therapeutics Inc, a
privately held developer of novel treatments of the Inflammasome
(NLRP3) Pathway based in San Diego, California. Mr. Werner
previously co-founded and served as Chief Operating Officer of
Eyevance Pharmaceuticals through its sale to Santen Pharmaceuticals
Ltd. He has held a variety of commercial development roles and
corporate strategy positions at companies such as Sun Pharma, Nicox
SA and Inspire Pharmaceuticals, all within the field of
ophthalmics. Mr. Werner received his B.S. in business
administration from the University of New Hampshire.
“Since joining Alimera’s Board of Directors earlier this year, I
have had the privilege of working closely with this great team as
we integrated the YUTIQ brand and completed a successful
recapitalization of the balance sheet,” said Mr. Werner. “I
strongly believe the recent acquisition of the YUTIQ brand along
with the global growth of ILUVIEN will be transformational for
Alimera and I am excited to be in a position to meaningfully
contribute to the company’s continued growth in the retina
space.”
Mr. Eiswirth added, “I look forward to Alimera’s benefitting
from Philip’s established expertise in commercial operations in his
newly expanded role as we look to continue growing utilization of
ILUVIEN across all of our international markets.”
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose
mission is to be invaluable to patients, physicians and partners
concerned with retinal health and maintaining better vision longer.
For more information, please visit www.alimerasciences.com.
For investor inquiries: |
For media inquiries: |
Scott Gordon |
Jules Abraham |
for Alimera Sciences |
for Alimera Sciences |
scottg@coreir.com |
julesa@coreir.com |
|
|
Forward Looking Statements
This press release includes “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, Alimera’s expectations with respect
to its business strategy, future operations, projected growth, and
anticipated impact of the YUTIQ acquisition. Words such as
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“plan,” “contemplates,” “predict,” “project,” “target,” “likely,”
“potential,” “continue,” “ongoing,” “will,” “would,” “should,”
“could,” or the negative of these terms and similar expressions or
words, identify forward-looking statements. Forward-looking
statements are based on current expectations and involve inherent
risks and uncertainties (some of which are beyond Alimera’s
control), including factors that could delay, divert or change any
of them, and could cause actual results to differ materially from
those projected in these forward-looking statements. These risks
and uncertainties include, but are not limited to, those factors
discussed in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of Alimera’s most recently filed Annual Report on Form 10-K, most
recently filed Quarterly Report on Form 10-Q, and any of Alimera’s
subsequent filings with the Securities and Exchange Commission
(SEC) and available on the SEC’s website at www.sec.gov.
All forward-looking statements contained in this press release
are expressly qualified by the cautionary statements contained or
referred to herein. Alimera cautions investors not to rely on the
forward-looking statements Alimera makes or that are made on its
behalf as predictions of future events. These forward-looking
statements speak only as of the date of this press release. Alimera
undertakes no obligation to publicly update or revise any of the
forward-looking statements made in this press release, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities laws.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/293f689b-268e-441c-b135-adb9d8fa9ba2
Alimera Sciences (NASDAQ:ALIM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alimera Sciences (NASDAQ:ALIM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024